A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

NCT04712110 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Interventions

BIOLOGICAL: TAK-019
BIOLOGICAL: Placebo

Sponsor

Takeda